Current Study
Sleep Apnoea | ENLIGHTEN-3
The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnoea and obesity or overweight.
Study Overview
Location
Spearwood
Phase
Phase III
Study Duration
76 weeks
Main Entry Criteria
- Sleep Apnoea: You have a confirmed diagnosis of moderate-to-severe Obstructive Sleep Apnoea (OSA), backed by an overnight sleep test showing at least 15 breathing pauses per hour
- Body Weight: You have a Body Mass Index (BMI) of 27 or higher.
- Weight Stability: Your body weight has stayed stable (changing by less than 5%) for at least 3 months before starting the study.
- Diet History: You have tried to lose weight through dieting at least once in the past without lasting success.
Main Exclusion Criteria
- Weight-Loss Procedures: Prior or planned weight-loss surgeries, endoscopic procedures, or weight-loss devices (cosmetic procedures like lipo or tummy tucks are allowed if done over a year ago; removed weight-loss devices are allowed if removed over 6 months ago).
- Airway Surgeries: Any past or upcoming sleep apnoea or major ear, nose, or throat (ENT) surgery that could still affect breathing.
- Diabetes: Diagnosis of type 1, type 2, or any other form of diabetes.
- Recent Heart Events (Last 90 Days): A recent heart attack, stroke, heart artery procedure, unstable chest pain, or hospital stay for severe heart failure.
- Severe Heart Failure: A history of Class IV (most severe) congestive heart failure.
- Recent Weight-Loss Medications: Use of any weight-loss prescription drugs, over-the-counter supplements, or herbal remedies within 90 days of joining.
Assessments
At a Glance
Clinic Visits
Phone Calls
Duration
76 weeks